Consensus on diagnosis and management of Cushing's disease: a guideline update

M Fleseriu, R Auchus, I Bancos… - The lancet Diabetes & …, 2021 - thelancet.com
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term
management to optimise patient outcomes. The Pituitary Society convened a consensus …

Diagnosis and management of pituitary adenomas: a review

NA Tritos, KK Miller - Jama, 2023 - jamanetwork.com
Importance Pituitary adenomas are neoplasms of the pituitary adenohypophyseal cell
lineage and include functioning tumors, characterized by the secretion of pituitary hormones …

[HTML][HTML] Phase 2 trial of baxdrostat for treatment-resistant hypertension

MW Freeman, YD Halvorsen, W Marshall… - … England Journal of …, 2023 - Mass Medical Soc
Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …

Medical treatment of Cushing's disease: an overview of the current and recent clinical trials

R Pivonello, R Ferrigno, MC De Martino… - Frontiers in …, 2020 - frontiersin.org
Cushing's disease (CD) is a serious endocrine disorder characterized by chronic
hypercortisolism, or Cushing's syndrome (CS), caused by a corticotroph pituitary tumor …

Cushing syndrome: a review

M Reincke, M Fleseriu - Jama, 2023 - jamanetwork.com
Importance Cushing syndrome is defined as a prolonged increase in plasma cortisol levels
that is not due to a physiological etiology. Although the most frequent cause of Cushing …

Glucose and lipid metabolism abnormalities in C ushing's syndrome

R Salehidoost, M Korbonits - Journal of Neuroendocrinology, 2022 - Wiley Online Library
Prolonged excess of glucocorticoids (GCs) has adverse systemic effects leading to
significant morbidities and an increase in mortality. Metabolic alterations associated with the …

Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension

M Fleseriu, J Newell-Price, R Pivonello… - European journal of …, 2022 - academic.oup.com
Objective To investigate the long-term efficacy and tolerability of osilodrostat, a potent oral
11β-hydroxylase inhibitor, for treating Cushing's disease (CD). Design/methods A total of …

Glucocorticoid withdrawal syndrome following treatment of endogenous Cushing syndrome

X He, JW Findling, RJ Auchus - Pituitary, 2022 - Springer
Abstract Purpose: Literature regarding endogenous Cushing syndrome (CS) largely focuses
on the challenges of diagnosis, subtyping, and treatment. The enigmatic phenomenon of …

Approach to the patient treated with steroidogenesis inhibitors

F Castinetti, LK Nieman, M Reincke… - The Journal of …, 2021 - academic.oup.com
Steroidogenesis inhibitors can be given to control the hypercortisolism of Cushing's
syndrome in various situations: when surgery has been unsuccessful or not possible; in …

Randomized trial of osilodrostat for the treatment of Cushing disease

M Gadelha, M Bex, RA Feelders… - The Journal of …, 2022 - academic.oup.com
Context Cushing disease, a chronic hypercortisolism disorder, is associated with
considerable morbidity and mortality. Normalizing cortisol production is the primary …